Key Details
Price
$4.10Annual EPS
-$1.48Annual ROE
45.94%Beta
1.83Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120778&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Jan. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) (NASDAQ: KYTX) and certain of its officers.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120649&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / January 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120662&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120656&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120739&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
NEW YORK, Jan. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline.
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kyverna-therapeutics-inc-lawsuit-submission-form?prid=120643&wire=1 or contact Joseph E. Levi, Esq.
FAQ
- What is the primary business of Kyverna Therapeutics Common Stock?
- What is the ticker symbol for Kyverna Therapeutics Common Stock?
- Does Kyverna Therapeutics Common Stock pay dividends?
- What sector is Kyverna Therapeutics Common Stock in?
- What industry is Kyverna Therapeutics Common Stock in?
- What country is Kyverna Therapeutics Common Stock based in?
- When did Kyverna Therapeutics Common Stock go public?
- Is Kyverna Therapeutics Common Stock in the S&P 500?
- Is Kyverna Therapeutics Common Stock in the NASDAQ 100?
- Is Kyverna Therapeutics Common Stock in the Dow Jones?
- When was Kyverna Therapeutics Common Stock's last earnings report?
- When does Kyverna Therapeutics Common Stock report earnings?
- Should I buy Kyverna Therapeutics Common Stock stock now?